Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
As Ray said, we would need a Big Pharma. Maybe someone like Novartis. AZ took the Jenner vaccine early;
The potential vaccine entered Phase I clinical trials last week to study safety and efficacy in healthy volunteers aged 18 to 55 years, across five trial centres in Southern England. Data from the Phase I trial could be available next month. Advancement to late-stage trials should take place by the middle of this year.
AstraZeneca and the University of Oxford today announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from SARS-CoV-2.
https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-and-oxford-university-announce-landmark-agreement-for-covid-19-vaccine.html
Bill, the link you provided was from April last year. Was that an error?
Not a mistake krafty,
I am just illustrating what the AZ/Oxford deal looked like. Hopefully Scancell can attract a big player if the data is good enough.
There is a mix of possibilities with Cepi and UK government involvement.
I think CEPI would like the no needle delivery
Ray totally agree about CEPI and the delivery... it fits in with what they are looking for perfectly ... It's like scancell /team Notts and ticking every single box..... can't be being ignored it just can't be!
Again the amount of science in Coividty is just wow... it's beyond next-gen ImmunoBody... you have AvidiMaB in there a product with absolutely massive potential .... you now have the possibility of a stable for years DNA vax being delivered via a spay or microneedle patch.... that will include cancer vaccines!... no more electroporation issues ! Suck on that Inovio lol.... then the actual 'simple non-toxic peptide delivery' .... it could deliver all those mRNA vaxs too!... immense I hope it comes in-house and that that is part of the coming further Covidity updates....
Next ...moditope :)))))
Have the two needle free delivery methods been made public ? if so can somebody share what they are ?
Cheers
The closest we know:
https://www.findaphd.com/phds/project/development-of-an-intradermal-or-inhaled-dna-vaccine-for-covid-19-and-beyond/?p127093
'Intradermal and inhaled delivery of nucleic acid vaccines could be clinically effective, safe and globally-deployable against multiple complex diseases. This project will aim to combine physical and peptide-based delivery systems to enhance the efficacy and application of such technologies to the COVID-19 vaccine (‘Covidity’) '
'The platform technology optimised and demonstrated will have wide ranging impact on future applications of nucleic acid vaccine approaches (including DNA, mRNA and oligo-based methods). '
Massive that... been waved right under BioNTechs nose too ....
Crumbs,
I think that particular icase funded PhD doesn't start until the new academic year in October (see link below). That's not to say that James Dixon's team haven't already come up with needle free delivery systems but don't rule out the chances of Scancell using a proprietary system.
https://www.nottingham.ac.uk/pgstudy/courses/doctoral-training-programmes/mrc-integrated-midlands-partnership-for-biomedical-training.aspx
'Summary:
Numerous approaches have been undertaken to develop ways of stimulating the cellular immune response to eradicate tumours, known as cancer vaccines or immunotherapy. Both the selection of the antigen expressed by the tumour and subsequent recruitment of CD4 and CD8 T cells; in combination with the delivery technology used to promote transfection of the DNA/RNA and delivery of the encoded RNA/DNA antigen to antigen presenting cells (APCs) are vital to an effective vaccine. Simple injection without a delivery system fails to transfect sufficient APCs to generate an immune response.
This project is to combine world-leading expertise in drug delivery and cancer immunology. Specifically, we will test our hypothesis that targeting RNA/DNA to lymphoid tissue through the use of intradermal delivery with microneedles and nanocomplexes will increase the uptake and translation of RNA/DNA by APCs.
Based on complexation of DNA/RNA with a cationic polymer or liposome, we will optimise the DNA or RNA polymer and lipid ratios to create a range of nanocomplexes. Next, uptake and translation in vitro of the nanocomplexes will be evaluated in dendritic cells. Bioluminescence imaging will then be used to monitor RNA and DNA targeting/translation to lymphoid tissue in vivo and anti-tumour studies conducted in collaboration with Scancell (https://www.scancell.co.uk/).
This project is a collaboration between academics in the School of Pharmacy (ranked 6th in the 2018 QS World Rankings for pharmacy and pharmacology) and Scancell (Cancer Immunotherapy SME).
Supervisors: Snow Stolnik, Pavel Gershkovich and Lindy Durrant (Scancell)'
Been work going on around it for a while methinks... and I think it will be an in-house as in Notts solution
Crumbs,
Thanks for that. Perhaps they'll use one of each (new UoN method and tried and tested proprietary method as a control). Who knows? No doubt all will become clear soon enough.
Berm still lots we don't know about lol...Lindy though has for a long time been proactive in looking for solutions for delivery as I think we can agree on electroporation although effective is not very practical or pleasant!.... It will be good to hear more details.... I'm sure somewhere I have seen in print 'microneedles' as a potential delivery for covidity I just can't remember or find where or imagined it :)..... I'm very excited at this progress though and hope it is just the beginning of great Covidity newsflow... and not another 18 weeks of waiting and wondering....
crumbs
you didn't imagine it
https://gtr.ukri.org/projects?ref=studentship-2276807
"This project is to combine world-leading expertise in drug delivery and cancer immunology. Specifically, we will test our hypothesis that targeting RNA/DNA to lymphoid tissue through the use of intradermal delivery with microneedles and nanocomplexes will increase the uptake and translation of RNA/DNA by APCs."
'This project is a collaboration between academics in the School of Pharmacy (ranked 6th in the 2018 QS World Rankings for pharmacy and pharmacology) and Scancell (Cancer Immunotherapy SME).'